KLRC1 and head and neck squamous cell carcinoma: Finally, blockade of inhibitory receptors with anti-NKG2A antibody [monalizumab] synergized with PD-1 blockade in animal models and demonstrated an improved response rate in head and neck squamous cell carcinoma patients treated with a combination of anti-NKG2A and anti-EGFR, with the effect thought to have largely been mediated via CD8 T cells [293].